Durable remission with salvage second autotransplants in patients with multiple myeloma. - Wikidata - wikimedia - TriplyDB

Durable remission with salvage second autotransplants in patients with multiple myeloma.

Durable remission with salvage second autotransplants in patients with multiple myeloma.

http://www.wikidata.org/entity/Q33685400

about

First line vs delayed transplantation in myeloma: Certainties and controversies American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers Salvage second hematopoietic cell transplantation in myeloma Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.Second autologous transplant as salvage therapy in multiple myeloma.Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.Second auto-SCT for treatment of relapsed multiple myeloma.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.When to recommend a second autograft in patients with relapsed myeloma?Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma.Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents.

P2860

Q26745957-B52A8BA8-148E-43B1-9419-46782DED9BA2 Q26782868-7E19B934-B08E-4088-80E7-00CF7DAD9D18 Q26851202-67F16051-E53E-406A-8F58-7FAB6A0BCC02 Q30416452-B43D485F-5DE1-47B9-9273-3291FC86EDAA Q33731691-2534669B-AC70-4942-96E3-EF674DB2AF56 Q36138646-3F086648-0C93-4FBB-BBF5-96F3D59A49E0 Q37627044-5F1941A9-C577-4680-B740-98C5423BDFD1 Q38151157-4823D8F6-CAA3-43C5-B43E-581D68D89DF0 Q38895415-1809DBAF-C749-4EBD-B8CB-F6E411E7203C Q39379927-7425F495-DF47-4841-9186-DEEEEB866BF5 Q44385832-C2EA669F-1033-45F6-85CE-6F249B962497 Q44647283-A7D9F5A2-1AFE-4880-95C5-4712E527A541 Q44758991-7BC6EE08-6395-4C36-8D27-91DDB7D822BB Q48139344-5EAE17EC-A91A-47C3-8FB2-09AB85332C15 Q48250743-9A464C6F-D85F-487F-9782-FB340C46C51D Q48921667-609EEC43-93CA-4847-A32C-936DC0C5931A Q53112373-C0C01713-D630-4BEB-A136-EB474D4DACF5 Q53116533-8C87F799-19CD-4FCF-A33B-14FD1E5C65B0 Q53146498-5EDEF84D-B887-45C2-976E-F7134EFCA170

P2860

Durable remission with salvage second autotransplants in patients with multiple myeloma.

http://www.wikidata.org/entity/Q33685400

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@ast

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@en

type

label

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@ast

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@en

prefLabel

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@ast

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@en

P1433

Q33685400-CFDB145B-198B-4D45-AC43-18FADBF440CF

P1476

Q33685400-87FB65B4-5F3D-494A-A30C-D36C988815B8

P2093

Q33685400-27149463-01CE-4ECA-B34A-C8490FFD2D88

Q33685400-2A85EE2B-3C0A-4DDA-B2AD-26E00CABA2F2

Q33685400-2D6C65C6-5609-4240-A831-5BE80FED5CDF

Q33685400-43BF8533-B707-4C23-B4BB-E8D4CF5CD6C9

Q33685400-710368F7-8B20-4167-96FE-81F632EF69DC

Q33685400-8E7F374B-19FF-4041-A05B-CA625D9731D9

Q33685400-9AC3469F-B235-423E-8141-24DA551B9013

Q33685400-B051A703-5D01-4C1A-8E9D-5FB6BE92D79C

Q33685400-C07081B5-1832-4C9A-9C10-3783DD7C8124

Q33685400-CD6BDB2E-8816-45B6-8C8B-9BF10C0CC52E

P2860

Q33685400-1AFA6C47-5448-403A-A308-C59EE978829C

Q33685400-29DE74ED-4F95-467D-82B4-FC40B670FE43

Q33685400-328C533C-694A-4366-ADDA-332CC81A086B

Q33685400-394CF71C-5BCF-49C1-B8A6-3AF2C72AC577

Q33685400-49C392C7-7ACD-4347-87EA-0B002298F917

Q33685400-4EE6E1BD-D870-45BF-A68D-75AD2227812A

Q33685400-505C0B77-5070-4265-BDDF-DE5637655AF8

Q33685400-53388A9A-7CC0-4F3B-95A0-7862E528FAF6

Q33685400-5438FC08-3230-4D21-A551-6225B12CE1FF

Q33685400-81364AA3-2E64-4C65-AA28-1D97CC89331B

P304

Q33685400-86D5A702-FA8E-4118-8367-1A69C00A3C5E

P31

Q33685400-23E079F5-A110-4990-B2CE-8A94B5608469

P356

Q33685400-42886F4E-50D9-4B7F-ACC7-825522FCEFC1

P407

Q33685400-AF75874D-B1A6-4481-BA71-2E836DC1BC5F

P433

Q33685400-F723F82D-3A57-4FA9-A201-ACBF601573F6

P478

Q33685400-A41A5BA2-B48A-4918-B4D8-206B98C8932B

P50

Q33685400-82EAB12D-BCB6-4446-A483-F8DD7BAD68DD

P577

Q33685400-433641FF-B4C1-4DEF-AF00-ABE3AB673F0D

P5875

Q33685400-42E4FE15-D896-4E1F-A8E6-521D976F1313

P698

Q33685400-340E7C07-91DA-4A4B-9BB9-7E2D247E929E

P921

Q33685400-CD7E2553-32D4-4521-9A15-870A30F9E3AC

P932

Q33685400-60E0881A-8919-4E80-96A4-F329A34B51ED

P356

P1433

P1476

Durable remission with salvage second autotransplants in patients with multiple myeloma.

@en

P2093

Fraz Ahmed

http://www.w3.org/2001/XMLSchema#string

Gabriela Rondon

http://www.w3.org/2001/XMLSchema#string

Hassan Khan

http://www.w3.org/2001/XMLSchema#string

Muzaffar H Qazilbash

http://www.w3.org/2001/XMLSchema#string

Nina Shah

http://www.w3.org/2001/XMLSchema#string

Peter Thall

http://www.w3.org/2001/XMLSchema#string

Qaiser Bashir

http://www.w3.org/2001/XMLSchema#string

Richard Champlin

http://www.w3.org/2001/XMLSchema#string

Sijin Wen

http://www.w3.org/2001/XMLSchema#string

Sofia Qureshi

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple myeloma

Nonparametric Estimation from Incomplete Observations

Estimating the Dimension of a Model

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

P304

3549-3555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26662

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51801747

http://www.w3.org/2001/XMLSchema#string

P698

22086552

http://www.w3.org/2001/XMLSchema#string

P921

autotransplantation

P932

4038445

http://www.w3.org/2001/XMLSchema#string